RxDoctor Payments Data

Christian Edward Dyhianto, MD

Family Medicine · Magnolia, TXNPI 1164688099

Payments from drug & device makers

$17,340in general payments, 2019–2025

Across 915 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$2K
  • AbbVie$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Lilly USA, LLC$1K
  • GSK$774
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$1,2007%
  • Food & beverage$16,04593%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk152$2,594
AstraZeneca91$1,946
AbbVie(2 entities)138$1,860
Biohaven Pharmaceuticals, Inc.8$1,312
Lilly USA, LLC66$1,035
GSK39$774
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC61$651
Boehringer Ingelheim33$613
Supernus Pharmaceuticals, Inc.7$460
Pfizer21$428
Amgen(2 entities)25$398
Exact Sciences22$388
Bayer12$386
Astellas Pharma US Inc18$360
Johnson & Johnson15$346
Abbott18$297
Paratek Pharmaceuticals, Inc.21$289
Amarin Pharma, Inc.15$289
Otsuka America Pharmaceutical, Inc.11$280
Takeda Pharmaceuticals U.S.A., Inc.14$262
Axsome Therapeutics, Inc.8$216
Medtronic(2 entities)5$211
Merck18$197
Biohaven Pharmaceutical Holding Company Ltd.7$161
Esperion Therapeutics, Inc.8$146
E.r. Squibb & Sons, L.L.C.1$124
Sanofi-aventis U.S. LLC8$110
Shire North American Group Inc6$91
Daiichi Sankyo Inc.4$91
Antares Pharma, Inc.6$91
Arbor Pharmaceuticals, Inc.6$87
Azurity Pharmaceuticals, Inc.3$55
Corium, LLC5$55
Eisai Inc.3$51
Halozyme Inc3$51
Dexcom, Inc.2$47
Phathom Pharmaceuticals, Inc.4$47
Tolmar, Inc.2$40
Acella Pharmaceuticals, LLC2$36
Romark Laboratories, LC2$34
Adlon Therapeutics L.p.2$33
Melinta Therapeutics, LLC2$32
Currax Pharmaceuticals LLC2$31
Novartis1$27
Kyowa Kirin, Inc.1$26
Lundbeck LLC1$26
Teva Pharmaceuticals USA, Inc.2$25
Radius Health, Inc.1$23
Jazz Pharmaceuticals Inc.1$22
Idorsia Pharmaceuticals US Inc1$21
Hologic Sales And Service, LLC1$20
Verity Pharmaceuticals Inc.1$20
Tris Pharma Inc1$18
Vertiflex, Inc.1$18
Optinose US, Inc.1$18
Upsher-smith Laboratories LLC1$17
Cranial Technologies, Inc1$13
Nalpropion Pharmaceuticals LLC1$12
Circassia Inc.1$11
Ironwood Pharmaceuticals, Inc1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,340 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$180,837
Medicare patients
245
Services billed
2,786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol113$128,599
OzempicSemaglutide96$126,947
MounjaroTirzepatide61$75,330
JardianceEmpagliflozin53$56,188
EliquisApixaban28$36,430
JanuviaSitagliptin Phosphate30$29,070
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$28,800
TrulicityDulaglutide16$26,364
Repatha SureclickEvolocumab21$20,214
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$20,074
Synjardy XrEmpagliflozin/Metformin Hcl11$19,167
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$17,157
Soliqua 100-33Insulin Glargine/Lixisenatide11$16,021
Xigduo XrDapaglifloz Propaned/Metformin11$13,986
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$4,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,946$148,673139 claims
Novo NordiskOzempic$2,594$126,94796 claims
Lilly USA, LLCMounjaro, Trulicity$1,035$101,69477 claims
Boehringer IngelheimJardiance, Synjardy Xr$613$75,35564 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy$774$50,39969 claims
PfizerEliquis$428$36,43028 claims
MerckJanuvia$197$29,07030 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$110$16,02111 claims
AbbVieArmour Thyroid$1,860$1,77023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Magnolia

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →